Literature DB >> 11524727

Promoting appropriate antimicrobial drug use: perspective from the Centers for Disease Control and Prevention.

D M Bell1.   

Abstract

Extending the useful life of antimicrobial drugs through appropriate use-that is, use that maximizes therapeutic impact while minimizing toxicity and the development of resistance-is an important component of efforts to prevent and control the emerging threat of antimicrobial resistance. The major paradigms of antimicrobial drug use involve acute infections in outpatients, acute infections in inpatients, chronic infections, and agriculture/veterinary medicine. The factors that influence drug use and the challenges that need to be addressed in promoting more appropriate use are different in each of these paradigms. For acute respiratory infections in outpatients, data from intervention trials suggest that concurrent multifaceted interventions may be effective in promoting appropriate drug prescribing. The next challenge is to extend these interventions to larger populations by incorporating them into routine medical practice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11524727     DOI: 10.1086/321857

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

1.  Disease progression in hemodynamically stable patients presenting to the emergency department with sepsis.

Authors:  Seth W Glickman; Charles B Cairns; Ronny M Otero; Christopher W Woods; Ephraim L Tsalik; Raymond J Langley; Jennifer C van Velkinburgh; Lawrence P Park; Lawrence T Glickman; Vance G Fowler; Stephen F Kingsmore; Emanuel P Rivers
Journal:  Acad Emerg Med       Date:  2010-04       Impact factor: 3.451

Review 2.  Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia.

Authors:  Steven D Brown
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 3.  Encouraging rational antibiotic use in childhood pneumonia: a focus on Vietnam and the Western Pacific Region.

Authors:  Nguyen T K Phuong; Tran T Hoang; Pham H Van; Lolyta Tu; Stephen M Graham; Ben J Marais
Journal:  Pneumonia (Nathan)       Date:  2017-04-25

4.  Antimicrobial Resistance or Delayed Appropriate Therapy-Does One Influence Outcomes More Than the Other Among Patients With Serious Infections Due to Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacteriaceae?

Authors:  Thomas P Lodise; Ariel Berger; Arman Altincatal; Rosa Wang; Tarun Bhagnani; Patrick Gillard; Nicole G Bonine
Journal:  Open Forum Infect Dis       Date:  2019-04-23       Impact factor: 3.835

5.  Impact of combination therapy with aminoglycosides on the outcome of ICU-acquired bacteraemias.

Authors:  P-Y Delannoy; N Boussekey; P Devos; S Alfandari; C Turbelin; A Chiche; A Meybeck; H Georges; O Leroy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-15       Impact factor: 3.267

6.  Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study.

Authors:  Jordi Vallés; Ignacio Martin-Loeches; Antoni Torres; Emili Diaz; Iratxe Seijas; Maria José López; Pau Garro; Carlos Castillo; Jose Garnacho-Montero; María del Mar Martin; Maria Victoria de la Torre; Pedro Olaechea; Catia Cilloniz; Jordi Almirall; Fernando García; Roberto Jiménez; Estrella Seoane; Cruz Soriano; Eduard Mesalles; Pilar Posada
Journal:  Intensive Care Med       Date:  2014-03-18       Impact factor: 17.440

7.  An initiative to improve adherence to evidence-based guidelines in the treatment of URIs, sinusitis, and pharyngitis.

Authors:  Richard Alweis; Michael Greco; Thomas Wasser; Suzanne Wenderoth
Journal:  J Community Hosp Intern Med Perspect       Date:  2014-02-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.